Company: APXIF
Filing Date: 2025-06-11
Form Type: 10-Q
Source: 0001213900-25-053185
Chunk: 155

Company: APx Acquisition Corp. I
Filing Date: 2025-06-11
Form: 10-Q
Item: Part I, Item 2
Chunk 155
---
ating to Company Shares and Company Warrants to be issued in the Merger; (c) Nasdaq listing approval of
the Company Shares and Company Warrants; (d) absence of any law, rule, regulation, judgment, decree, executive order or award which
is then in effect and has the effect of making the Proposed Business Combination illegal or otherwise prohibiting consummation of the
Proposed Business Combination; and I the Company or OmnigenicsAI having at least $5,000,001 of net tangible assets.

The obligation of the
Company to consummate the Proposed Business Combination is subject to certain additional conditions at or prior to the Closing, including
(a) the accuracy of certain representations and warranties of OmnigenicsAI, MultiplAI and Merger Sub except, with respect to certain
representations and warranties required to be true and correct in all respects, where the failure of such representations and warranties
to be true and correct does not result in a Company Material Adverse Effect or MultiplAI Material Adverse Effect or is not materially
adverse to Merger Sub, as applicable; (b) OmnigenicsAI’s and Merger Sub’s performance or compliance in all material respects
with all agreements and covenants required by the Business Combination Agreement; (c) if the MultiplAI SPA has not been terminated
in accordance with its terms, MultiplAI’s performance or compliance in all material respects with all agreements and covenants required
by the Business Combination Agreement and MultiplAI SPA; (d) the consummation of the Restructuring; (e) the absence of any Company
Material Adverse Effect or, if the MultiplAI SPA has not been terminated in accordance with its terms, any MultiplAI Material Adverse
Effect; (f) if the MultiplAI SPA has not been terminated in accordance with its terms, the consummation of the MultiplAI Contribution;
and (g) OmnigenicsAI having, immediately prior to the Merger Effective Time, (i) no more than 34,000,000 issued and outstanding
Company Shares (on a fully diluted basis after consummation of the Restructuring and the MultiplAI Contribution) in addition to any Company
Shares issued pursuant to any PIPE Subscription Agreements and the Backstop Agreement; or (ii) if the transactions under the MultiplAI
SPA are not consummated and the